Logo image of ANIK

ANIKA THERAPEUTICS INC (ANIK) Stock Fundamental Analysis

NASDAQ:ANIK - Nasdaq - US0352551081 - Common Stock - Currency: USD

17.39  -0.26 (-1.47%)

After market: 17.39 0 (0%)

Fundamental Rating

4

Overall ANIK gets a fundamental rating of 4 out of 10. We evaluated ANIK against 571 industry peers in the Biotechnology industry. ANIK has a great financial health rating, but its profitability evaluates not so good. ANIK does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

In the past year ANIK has reported negative net income.
In the past year ANIK had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: ANIK reported negative net income in multiple years.
ANIK had a positive operating cash flow in 4 of the past 5 years.
ANIK Yearly Net Income VS EBIT VS OCF VS FCFANIK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M -40M -60M -80M

1.2 Ratios

ANIK's Return On Assets of -42.14% is in line compared to the rest of the industry. ANIK outperforms 53.29% of its industry peers.
The Return On Equity of ANIK (-54.22%) is better than 62.88% of its industry peers.
Industry RankSector Rank
ROA -42.14%
ROE -54.22%
ROIC N/A
ROA(3y)-11.21%
ROA(5y)-6.39%
ROE(3y)-14.24%
ROE(5y)-8.42%
ROIC(3y)N/A
ROIC(5y)N/A
ANIK Yearly ROA, ROE, ROICANIK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 -20 -30

1.3 Margins

ANIK has a better Gross Margin (62.70%) than 80.11% of its industry peers.
ANIK's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ANIK so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 62.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.37%
GM growth 5Y-2.54%
ANIK Yearly Profit, Operating, Gross MarginsANIK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 60

More info and screens

7

2. Health

2.1 Basic Checks

ANIK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ANIK has more shares outstanding
The number of shares outstanding for ANIK has been increased compared to 5 years ago.
ANIK has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ANIK Yearly Shares OutstandingANIK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M
ANIK Yearly Total Debt VS Total AssetsANIK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

ANIK has an Altman-Z score of 4.73. This indicates that ANIK is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 4.73, ANIK belongs to the best of the industry, outperforming 80.46% of the companies in the same industry.
There is no outstanding debt for ANIK. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.73
ROIC/WACCN/A
WACC9.44%
ANIK Yearly LT Debt VS Equity VS FCFANIK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M 200M 250M

2.3 Liquidity

A Current Ratio of 5.34 indicates that ANIK has no problem at all paying its short term obligations.
The Current ratio of ANIK (5.34) is comparable to the rest of the industry.
A Quick Ratio of 3.78 indicates that ANIK has no problem at all paying its short term obligations.
ANIK has a Quick ratio (3.78) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 5.34
Quick Ratio 3.78
ANIK Yearly Current Assets VS Current LiabilitesANIK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

ANIK shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -235.86%.
Looking at the last year, ANIK shows a small growth in Revenue. The Revenue has grown by 0.53% in the last year.
The Revenue has been growing by 9.56% on average over the past years. This is quite good.
EPS 1Y (TTM)-235.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.44%
Revenue 1Y (TTM)0.53%
Revenue growth 3Y8.49%
Revenue growth 5Y9.56%
Sales Q2Q%-6.54%

3.2 Future

Based on estimates for the next years, ANIK will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.81% on average per year.
The Revenue is expected to grow by 7.34% on average over the next years.
EPS Next Y50.41%
EPS Next 2Y40.08%
EPS Next 3Y27.36%
EPS Next 5Y17.81%
Revenue Next Year-9.03%
Revenue Next 2Y-16.72%
Revenue Next 3Y-9.04%
Revenue Next 5Y7.34%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ANIK Yearly Revenue VS EstimatesANIK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M 200M
ANIK Yearly EPS VS EstimatesANIK Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 2 -2 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ANIK. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANIK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANIK Price Earnings VS Forward Price EarningsANIK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ANIK indicates a rather cheap valuation: ANIK is cheaper than 94.14% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 51.66
ANIK Per share dataANIK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

ANIK's earnings are expected to grow with 27.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.08%
EPS Next 3Y27.36%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ANIK!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANIKA THERAPEUTICS INC

NASDAQ:ANIK (2/21/2025, 8:01:14 PM)

After market: 17.39 0 (0%)

17.39

-0.26 (-1.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-20 2025-02-20/amc
Earnings (Next)05-06 2025-05-06/amc
Inst Owners87.43%
Inst Owner Change-95.07%
Ins Owners2.88%
Ins Owner Change0.11%
Market Cap254.76M
Analysts87.5
Price Target27.03 (55.43%)
Short Float %2.72%
Short Ratio5.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-827.5%
Min EPS beat(2)-1533.99%
Max EPS beat(2)-121.01%
EPS beat(4)0
Avg EPS beat(4)-804.68%
Min EPS beat(4)-1533.99%
Max EPS beat(4)-62.81%
EPS beat(8)1
Avg EPS beat(8)-412.3%
EPS beat(12)4
Avg EPS beat(12)-271.06%
EPS beat(16)7
Avg EPS beat(16)-155.77%
Revenue beat(2)0
Avg Revenue beat(2)-6.05%
Min Revenue beat(2)-9.72%
Max Revenue beat(2)-2.38%
Revenue beat(4)2
Avg Revenue beat(4)-2.21%
Min Revenue beat(4)-9.72%
Max Revenue beat(4)1.75%
Revenue beat(8)5
Avg Revenue beat(8)0.9%
Revenue beat(12)9
Avg Revenue beat(12)2.82%
Revenue beat(16)12
Avg Revenue beat(16)3.07%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.55
P/FCF N/A
P/OCF 34.14
P/B 1.42
P/tB 1.51
EV/EBITDA 51.66
EPS(TTM)-4.87
EYN/A
EPS(NY)-0.2
Fwd EYN/A
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)0.51
OCFY2.93%
SpS11.21
BVpS12.28
TBVpS11.54
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -42.14%
ROE -54.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 62.7%
FCFM N/A
ROA(3y)-11.21%
ROA(5y)-6.39%
ROE(3y)-14.24%
ROE(5y)-8.42%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y5.37%
GM growth 5Y-2.54%
F-Score6
Asset Turnover0.71
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr 89.75%
Cap/Sales 5.4%
Interest Coverage N/A
Cash Conversion 200.4%
Profit Quality N/A
Current Ratio 5.34
Quick Ratio 3.78
Altman-Z 4.73
F-Score6
WACC9.44%
ROIC/WACCN/A
Cap/Depr(3y)41.93%
Cap/Depr(5y)37.03%
Cap/Sales(3y)3.84%
Cap/Sales(5y)3.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-235.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%44.44%
EPS Next Y50.41%
EPS Next 2Y40.08%
EPS Next 3Y27.36%
EPS Next 5Y17.81%
Revenue 1Y (TTM)0.53%
Revenue growth 3Y8.49%
Revenue growth 5Y9.56%
Sales Q2Q%-6.54%
Revenue Next Year-9.03%
Revenue Next 2Y-16.72%
Revenue Next 3Y-9.04%
Revenue Next 5Y7.34%
EBIT growth 1Y74.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year157.51%
EBIT Next 3Y36.1%
EBIT Next 5Y29.95%
FCF growth 1Y-160.39%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-11.15%
OCF growth 3YN/A
OCF growth 5YN/A